EU/3/14/1259 - orphan designation for treatment of nontuberculous mycobacterial lung disease

Amikacin sulfate

Overview

On 8 April 2014, orphan designation (EU/3/14/1259) was granted by the European Commission to Insmed Limited, United Kingdom, for amikacin sulfate for the treatment of nontuberculous mycobacterial lung disease.

The sponsor’s address was updated in February 2019.

The sponsorship was transferred to Insmed Netherlands B.V., Netherlands, in February 2019.

The sponsor’s address was updated in October 2020.

Amikacin sulfate has been authorised in the EU as Arikayce liposomal since 27 October 2020. 

What is nontuberculous mycobacterial lung disease?

Nontuberculous mycobacterial lung disease is an infection of the lungs by nontuberculous mycobacteria.

Nontuberculous mycobacteria (also known as environmental mycobacteria) are types of bacteria found widely in the environment, such as in water and in soil, but unlike other species of mycobacteria that cause tuberculosis and leprosy they do not usually cause disease in people. When they do cause disease, patients are infected by direct exposure to the bacteria in the environment and not from close contact with other people as can happen with tuberculosis and leprosy.

Lung infection with nontuberculous mycobacteria typically occurs in patients who already have lung disease or who have weakened immune systems. Symptoms include long-term coughing, excess sputum (phlegm) and tiredness and, less commonly, coughing up blood, difficulty breathing, fever and weight loss.

Nontuberculous mycobacterial lung disease is debilitating in the long term because of the lung damage caused by severe forms of the infection, which do not respond well to treatment.

What is the estimated number of patients affected by the condition?

At the time of designation, nontuberculous mycobacterial lung disease affected approximately 0.6 in 10,000 people in the European Union (EU). This was equivalent to a total of around 31,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 511,100,000 (Eurostat 2014).

What treatments are available?

At the time of designation, a number of antibiotics were authorised in the EU for treating nontuberculous mycobacterial lung disease.

The sponsor has provided sufficient information to show that amikacin might be of significant benefit for patients with nontuberculous mycobacterial lung disease because it is being developed as a medicine for inhalation and early studies show that it has better lung penetration and less frequent side effects compared with the intravenous (into a vein) antibiotics used to treat the condition. In addition, there is a possibility that, as a medicine for inhalation, patients may be able to use it outside of the hospital. These assumptions will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

Amikacin is an antibiotic that belongs to the group 'aminoglycosides'. It works by disrupting the production of proteins that bacteria need to build their cell walls, thereby damaging the bacteria and eventually killing them.

In this medicine, amikacin is contained within tiny fat particles known as liposomes, which can transport the medicine into the lungs when inhaled. As an inhalation medicine, it is expected to be better at penetrating the lung tissue and targeting bacteria in the lungs than intravenous medicines, while at the same time causing fewer side effects in the rest of the body.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with nontuberculous mycobacterial lung disease were ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for nontuberculous mycobacterial lung disease. Orphan designation of the medicine had been granted in the United States for the condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 6 February 2014 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/14/1259: Public summary of opinion on orphan designation: Amikacin sulfate for the treatment of nontuberculous mycobacterial lung disease

AdoptedReference Number: EMA/COMP/97247/2014 Rev.1

Key facts

• Active substance:
  Amikacin sulfate
• Intended use:
  Treatment of nontuberculous mycobacterial lung disease
• Orphan designation status:
  Positive
• EU designation number:
  EU/3/14/1259
• Date of designation:
  08/04/2014
• Sponsor:

  Insmed Netherlands B.V.; Stadsplateau 7; 3521 AZ Utrecht; Netherlands; Tel: [phone]; E-mail: [e-mail]

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Arikayce liposomal at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.

More information is available in the Arikayce liposomal : Orphan designation assessment report (initial authorisation).